These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27528400)

  • 41. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
    Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
    Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice.
    Berlin O; Samid D; Donthineni-Rao R; Akeson W; Amiel D; Woods VL
    Cancer Res; 1993 Oct; 53(20):4890-5. PubMed ID: 8402677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spontaneous and irradiation-induced tumor susceptibility in BRCA2 germline mutant mice and cooperative effects with a p53 germline mutation.
    McAllister KA; Houle CD; Malphurs J; Ward T; Collins NK; Gersch W; Wharey L; Seely JC; Betz L; Bennett LM; Wiseman RW; Davis BJ
    Toxicol Pathol; 2006; 34(2):187-98. PubMed ID: 16546942
    [TBL] [Abstract][Full Text] [Related]  

  • 44. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database.
    Ognjanovic S; Olivier M; Bergemann TL; Hainaut P
    Cancer; 2012 Mar; 118(5):1387-96. PubMed ID: 21837677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular pathogenesis of osteosarcoma.
    Kansara M; Thomas DM
    DNA Cell Biol; 2007 Jan; 26(1):1-18. PubMed ID: 17263592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer.
    Shimada S; Mimata A; Sekine M; Mogushi K; Akiyama Y; Fukamachi H; Jonkers J; Tanaka H; Eishi Y; Yuasa Y
    Gut; 2012 Mar; 61(3):344-53. PubMed ID: 21865403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased cathepsin D protein expression is a biomarker for osteosarcomas, pulmonary metastases and other bone malignancies.
    Gemoll T; Epping F; Heinrich L; Fritzsche B; Roblick UJ; Szymczak S; Hartwig S; Depping R; Bruch HP; Thorns C; Lehr S; Paech A; Habermann JK
    Oncotarget; 2015 Jun; 6(18):16517-26. PubMed ID: 26203049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.
    Moriarity BS; Otto GM; Rahrmann EP; Rathe SK; Wolf NK; Weg MT; Manlove LA; LaRue RS; Temiz NA; Molyneux SD; Choi K; Holly KJ; Sarver AL; Scott MC; Forster CL; Modiano JF; Khanna C; Hewitt SM; Khokha R; Yang Y; Gorlick R; Dyer MA; Largaespada DA
    Nat Genet; 2015 Jun; 47(6):615-24. PubMed ID: 25961939
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absence of the CD44 gene prevents sarcoma metastasis.
    Weber GF; Bronson RT; Ilagan J; Cantor H; Schmits R; Mak TW
    Cancer Res; 2002 Apr; 62(8):2281-6. PubMed ID: 11956084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between apoptosis and TP53 status in osteosarcoma.
    Pompetti F; Stuppia L; Gatta V; Calabrese G; Gamberi G; Benassi MS; Picci P; Palka G
    Cancer Genet Cytogenet; 1998 Sep; 105(2):177-81. PubMed ID: 9723038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
    Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
    Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Germ-line genetic variation of TP53 in osteosarcoma.
    Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
    Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SAS is amplified predominantly in surface osteosarcoma.
    Noble-Topham SE; Burrow SR; Eppert K; Kandel RA; Meltzer PS; Bell RS; Andrulis IL
    J Orthop Res; 1996 Sep; 14(5):700-5. PubMed ID: 8893761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation.
    Henriksen J; Aagesen TH; Maelandsmo GM; Lothe RA; Myklebost O; Forus A
    Oncogene; 2003 Aug; 22(34):5358-61. PubMed ID: 12917637
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Ignatius MS; Hayes MN; Moore FE; Tang Q; Garcia SP; Blackburn PR; Baxi K; Wang L; Jin A; Ramakrishnan A; Reeder S; Chen Y; Nielsen GP; Chen EY; Hasserjian RP; Tirode F; Ekker SC; Langenau DM
    Elife; 2018 Sep; 7():. PubMed ID: 30192230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.